In addition, it has been reported that the activated ubiquitin system in Dox-treated cancer cells promoted the degradation of the inhibitor for NF-κB, IκBα, possibly by K48-polyubiquitination [44,45] leading to the reduced anticancer effect of Dox. Here, NFKB1 is linked to cancer.